Certara (NASDAQ:CERT) Price Target Cut to $14.00 by Analysts at Barclays

Certara (NASDAQ:CERT) had its target price dropped by stock analysts at Barclays from $16.00 to $14.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 53.07% from the company’s current price.

CERT has been the topic of several other reports. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. UBS Group cut their price objective on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Certara in a research note on Wednesday, October 8th. Craig Hallum initiated coverage on shares of Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 target price for the company. Finally, KeyCorp upped their price target on shares of Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.38.

Certara Trading Down 18.8%

CERT stock traded down $2.12 during midday trading on Friday, reaching $9.15. 2,549,557 shares of the company traded hands, compared to its average volume of 1,713,118. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 184.28 and a beta of 1.44. Certara has a 52-week low of $8.64 and a 52-week high of $15.69. The business has a 50 day moving average of $11.82 and a 200-day moving average of $11.55. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same quarter in the previous year, the company posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, sell-side analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the sale, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. This represents a 40.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently modified their holdings of CERT. AdvisorNet Financial Inc purchased a new stake in shares of Certara in the second quarter valued at approximately $25,000. First Horizon Corp purchased a new position in shares of Certara in the third quarter valued at approximately $30,000. Versant Capital Management Inc boosted its stake in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after acquiring an additional 1,153 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Certara during the 1st quarter worth $31,000. Finally, Osaic Holdings Inc. grew its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.